Acura Pharmaceuticals (Acura Pharmaceuticals) Total Stockholders Equity : $0.18 Mil (As of Dec. 2021)

View and export this data going back to 1992. Start your Free Trial

What is Acura Pharmaceuticals Total Stockholders Equity?

Acura Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2021 was $0.18 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Acura Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2021 was $0.00. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Acura Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2021 was 1.12.

Acura Pharmaceuticals Total Stockholders Equity Historical Data

The historical data trend for Acura Pharmaceuticals's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acura Pharmaceuticals Total Stockholders Equity Chart

Acura Pharmaceuticals Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Stockholders Equity

Get a 7-Day Free Trial

-0.03

-3.62

-4.74

-5.89

0.18

Acura Pharmaceuticals Quarterly Data
	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21
Total Stockholders Equity	Get a 7-Day Free Trial															-5.89	-6.14	0.38	0.14	0.18

Acura Pharmaceuticals (OTCPK:ACUR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Acura Pharmaceuticals's Book Value per Share for the quarter that ended in Dec. 2021 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(0.178	-	0)	/	65.093
	=	0.00

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Acura Pharmaceuticals's Debt-to-Equity for the quarter that ended in Dec. 2021 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.033	+	0.167)	/	0.178
	=	1.12

Acura Pharmaceuticals Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Acura Pharmaceuticals's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Acura Pharmaceuticals (Acura Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Acura Pharmaceuticals Inc (OTCPK:ACUR) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

616 N. North Court, Suite 120, Palatine, IL, USA, 60067

Website

http://www.acurapharm.com

Acura Pharmaceuticals Inc is a specialty pharmaceutical company based in the United States. It is engaged in the research, development, and commercialization of technologies and products intended to address medication abuse and misuse. The company's product portfolio includes Limitx, Oxaydo, and Nexafed.

Executives

Bruce F Wesson	director	1827 PACIFIC ST BROOKLYN NY 11233
William G Skelly	director	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067
George K Ross	director	1350 TREAT BLVD SUITE 250 WALNUT CREEK CA 94596
James F Emigh	officer: VP, Corporate Development
Immanuel Thangaraj	director	10001 WOODLOCH FOREST DRIVE SUITE 175 THE WOODLANDS TX 77380
Robert A Seiser	officer: VP, Treasurer & Controller	C/O ACURA PHARMACEUTICALS, INC. 616 N. NORTH COURT SUITE 120 PALATINE IL 60067
Robert B Jones	officer: President & CEO	C/O ACURA PHARMACEUTICALS, INC. 616 N NORTH COURT PALATINE IL 60067
Albert W Brzeczko	officer: VP Pharmaceutical Sciences APT	C/O ACURA PHARMACEUTICALS, INC. 660 N. NORTH COURT PALATINE IL 60067
Peter A Clemens	officer: Senior VP & CFO	C/O HALSEY DRUG CO INC 1827 PACIFIC STREET BROOKLYN NY 11233
Abuse Deterrent Pharma, Llc	10 percent owner	333 EAST MAIN STREET SUITE 200 LOUISVILLE KY 40202
Claudius Llc	10 percent owner	C/O GALEN ASSOCIATES 610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020
John Schutte	10 percent owner	9707 SHELBYVILLE ROAD, LOUISVILLE KY 40233
Galen Partners Iii L P	10 percent owner	610 FIFTH AVE 5TH FL NEW YORK NY 10020
Galen Management, Llc	10 percent owner	680 WASHINGTON BLVD, STAMFORD CT 06901
Galen Employee Fund Iii Lp	10 percent owner	610 FIFTH AVENUE 5TH FLOOR NEW YORK NY 10020